TitulaerMMcCrackenLGabilondoI, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol2013; 12: 157–165.
2.
VerninoSO’NeillBPMarksRS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol2004; 6: 55–62.
3.
DalmauJLancasterEMartinez-HernandezE, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol2011; 10: 63–74.
4.
FordBMcDonaldASrinivasanS.Anti-NMDA receptor encephalitis: a case study and illness overview. Drugs Context2019; 8: 212589.
5.
HarrisonJCherukuriRBuchanD, et al. Renal cell carcinoma presenting with paraneoplastic hallucinations and cognitive decline from limbic encephalitis. J Gen Intern Med2015; 30: 1037–1040.
6.
YangIJarosJBegaD.Paraneoplastic peripheral nervous system manifestations of renal cell carcinoma: a case report and review of the literature. Case Rep Neurol2017; 9: 22–30.
7.
HughesEPengXGleichmanAJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci2010; 30: 5866–5875.
8.
DalmauJTüzünEWuH, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol2007; 61: 25–36.
9.
IizukaTSakaiFIdeT, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology2007; 70: 504–511.
